MX2016011852A - Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). - Google Patents

Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).

Info

Publication number
MX2016011852A
MX2016011852A MX2016011852A MX2016011852A MX2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A
Authority
MX
Mexico
Prior art keywords
polypeptide
seq
methods
amino acid
pulmonary fibrosis
Prior art date
Application number
MX2016011852A
Other languages
English (en)
Spanish (es)
Inventor
Lander Cynthia
Brophy Colleen
W Noble Paul
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of MX2016011852A publication Critical patent/MX2016011852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
MX2016011852A 2014-03-14 2015-03-12 Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). MX2016011852A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461953438P 2014-03-14 2014-03-14
PCT/US2015/020263 WO2015138784A2 (en) 2014-03-14 2015-03-12 Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)

Publications (1)

Publication Number Publication Date
MX2016011852A true MX2016011852A (es) 2017-05-09

Family

ID=54067793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011852A MX2016011852A (es) 2014-03-14 2015-03-12 Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).

Country Status (12)

Country Link
US (1) US20150258192A1 (OSRAM)
EP (1) EP3116543A4 (OSRAM)
JP (1) JP6655547B2 (OSRAM)
KR (1) KR20160124236A (OSRAM)
CN (1) CN106456758A (OSRAM)
AU (1) AU2015229251A1 (OSRAM)
BR (1) BR112016021000A2 (OSRAM)
CA (1) CA2942517A1 (OSRAM)
MX (1) MX2016011852A (OSRAM)
RU (1) RU2016140332A (OSRAM)
SG (1) SG11201607627RA (OSRAM)
WO (1) WO2015138784A2 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10705074B2 (en) 2015-09-25 2020-07-07 Cedars-Sinai Medical Center Targeting fibroblast invasion for pulmonary fibrosis
WO2019070908A1 (en) 2017-10-03 2019-04-11 Cedars-Sinai Medical Center METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS
JP7297104B2 (ja) * 2019-05-30 2023-06-23 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン 特発性肺線維症の動物モデル、その構築方法及び使用
EP4185382A4 (en) * 2020-07-24 2024-09-04 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2022147172A1 (en) * 2020-12-30 2022-07-07 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727564A1 (en) * 2004-03-17 2006-12-06 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
SG194135A1 (en) * 2011-04-12 2013-11-29 Matrix Inc Moerae Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2012142238A2 (en) * 2011-04-12 2012-10-18 Duke University Compositions and methods for the treatment of tissue fibrosis

Also Published As

Publication number Publication date
EP3116543A2 (en) 2017-01-18
KR20160124236A (ko) 2016-10-26
US20150258192A1 (en) 2015-09-17
CN106456758A (zh) 2017-02-22
JP2017509633A (ja) 2017-04-06
SG11201607627RA (en) 2016-10-28
EP3116543A4 (en) 2017-09-06
RU2016140332A3 (OSRAM) 2018-10-11
WO2015138784A3 (en) 2015-10-29
BR112016021000A2 (pt) 2017-10-03
RU2016140332A (ru) 2018-04-16
AU2015229251A1 (en) 2016-09-22
WO2015138784A2 (en) 2015-09-17
JP6655547B2 (ja) 2020-02-26
CA2942517A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
WO2015138784A3 (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis
MX2017016844A (es) Composiciones y procedimientos para tratar cancer.
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ZA202302340B (en) Compositions and methods for treating celiac sprue disease
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01713A (OSRAM)
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
WO2013013085A3 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
WO2009052489A3 (en) Novel inhibitors of mammalian tight junction opening
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
EA201991812A1 (ru) Композиции и способы для визуализации и лучевой терапии рака
MX2017008505A (es) Composicion.
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof